Tony Chen

Tony Chen has represented a broad range of life science clients in complex cross-border intellectual property matters relating to China since 2004.

Tony advises pharmaceutical and biotechnology companies on navigating China's pharmaceutical patent linkage system. He assists clients with procuring patents suitable for Orange Book listing and patent term extension and defending against patent invalidation challenges.

Tony advises Chinese biotechnology clients on patent protection of small molecules, biologics, gene therapy, cell therapy, gene editing, AI-enabled drug discovery, and RNA (ribonucleic acid) therapeutics. He supports IP license negotiations and advises investors on mitigating IP risks associated with investing in Chinese biotechnology companies.

Tony has worked with Jones Day's litigators in the United States and Europe in representing Chinese entrepreneurs and companies in litigation involving patent infringement, ITC 337 investigation, trade secret misappropriation, and economic espionage prosecution.

Tony trained in cell biology and molecular biology before studying law. He practiced patent law in California for more than a decade before moving to Shanghai. He was an in-house counsel for a leading specialty pharmaceutical company in California and a co-founder of a drug discovery technology company in Silicon Valley.

Tony was chairman of Bayhelix in 2020 and 2021, a panel member of the US-China IP Cooperation Dialogue, co-chair of the IP subcommittee of the American Chamber of Commerce in Shanghai, and an advisor to Shanghai Pudong New Area and Suzhou BioBay on the development of biotechnology industry.